How Do I Respond to an FDA Form 483 Within 15 Business Days?

A Form 483 is the list of observations an FDA investigator documents at the end of an inspection under the agency's inspection authority at Section 704 of the Federal Food, Drug, and Cosmetic Act. Receiving one is common; a substantial share of device manufacturer inspections end with at least one observation. What happens in the following 15 business days determines whether the matter closes quietly or escalates.

What a Form 483 Is, and Is Not

A Form 483 is the investigator's own observations, not a finding of violation and not a final agency action. FDA's Compliance Program Guidance Manual and Investigations Operations Manual describe the 483 as a communication tool, intended to give the firm an opportunity to correct conditions before FDA decides whether further action is warranted. The agency's actual determination happens later, after reviewing the firm's response and any follow up evidence, through the district office and, for more serious matters, the Office of Regulatory Affairs.

This distinction matters because it shapes the right response posture. A 483 is not something to contest line by line as though defending against a charge; it is an invitation to demonstrate that the firm's quality system found the same gap the investigator found, understands why it happened, and is already correcting it.

Why the 15 Business Day Clock Matters

FDA has no regulation requiring a response within 15 business days. The window exists because FDA's internal practice is to decide, roughly two to three weeks after the inspection closes, whether to issue a Warning Letter or take other action, and a firm's timely written response is the primary input to that decision. A response that arrives after FDA has already drafted a Warning Letter rarely changes the outcome. A response that arrives on time, with specifics FDA can verify, routinely prevents the escalation entirely.

The clock starts at the close of the inspection, the moment the investigator presents the Form 483 at the closeout meeting, not when the firm gets around to assigning someone to write the response.

What FDA Expects in a Complete Response

Every observation needs its own complete treatment. FDA's reviewers are trained to look for five elements on each one:

• Acknowledgement. A clear statement that the firm understands the observation and is not disputing the underlying fact pattern, even if it disagrees with the characterization.
• Root cause. An analysis of why the condition occurred, not just what occurred, typically using the firm's existing CAPA methodology under the quality system regulation (21 CFR Part 820, now the QMSR effective February 2026).
• Correction. The immediate fix to the specific instance the investigator cited.
• Corrective action. The systemic change that prevents recurrence, distinct from the one-time correction above.
• Evidence and timeline. Documentation that the correction has already happened where possible, plus a realistic, dated plan for anything still in progress.

A response built around this structure, observation by observation, is what FDA's own guidance describes as adequate. A general letter promising "we take this seriously and are reviewing our procedures" without this structure reads as evasive regardless of intent.

Common Mistakes That Turn a 483 Into a Warning Letter

The pattern across escalated cases is consistent. The most frequent mistakes: treating the 483 as a document to argue with rather than respond to; addressing only the observations that seem most serious and summarizing the rest; promising corrective actions without evidence that any work has started; and missing the 15 business day window because internal sign off took longer than expected. Each of these signals to FDA that the firm's quality system, not just the specific finding, has a gap.

What to Do When a Corrective Action Cannot Finish in 15 Days

Most meaningful corrective actions, a procedure rewrite, a training rollout, a supplier requalification, cannot genuinely complete within 15 business days, and FDA does not expect them to. What matters is that the response goes out on time regardless, with completed items marked complete, remaining items given a specific date rather than a vague commitment, and any interim containment measure described. A response that is honest about an open item with a credible plan is treated far better than a response that claims false completion to hit the deadline.

ADB's regulatory team drafts 483 responses against this exact structure as part of its 483 Response and Remediation service, mapping each observation to a root cause and corrective action the firm's own quality system can sustain, not a one-time fix written to satisfy the deadline.

Frequently Asked Questions

Is a Form 483 the same as a Warning Letter?

No. A Form 483 lists an investigator's observations at the close of an inspection; it is not a final agency determination of a violation. A Warning Letter is a more serious escalation FDA issues when it concludes the firm's response was inadequate or the violations are significant enough to warrant formal notice.

What happens if a corrective action cannot be completed within 15 business days?

The response still goes out on time, with completed actions described as complete and remaining actions given a specific, realistic completion date and interim containment measures. FDA does not expect every corrective action fully implemented in 15 days; it expects a credible plan and evidence that work has already started.

Does a 483 response need to address every observation?

Yes. Every discrete observation on the form needs its own root cause analysis, correction, corrective action, and supporting evidence. A response that addresses some observations thoroughly and others with a general statement reads as incomplete and invites a more serious follow up.